ArticleBreast cancer (Dove Medical Press)2025
Comprehensive Analysis and Experimental Validation of Single-Cell and Transcriptome Sequencing Reveal SGO2 as a Novel Biomarker for Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: SGO2 maintains the binding of sisters chromatids by protecting the adhesive complex at the centromere, thus ensuring the correct separation of chromosomes during mitosis and meiosis. And this study explored its role in breast cancer (BC) progression. Methods: SGO2 expression in breast cancer was analyzed utilizing data from TCGA, GTEX, and HPA databases. Our study leveraged clinical data to predict outcomes. Subsequently, we conducted a GSEA enrichment analysis, dove into co-expression profiling, explored immune cell infiltration patterns, examined drug sensitivity, and analyzed single-cell data. To delve deeper, we validated the functional role of SGO2 through in vitro cellular experiments. Results: Survival analysis demonstrated a notable correlation between heightened SGO2 expression and unfavorable cancer survival rates. Gene set enrichment analysis (GSEA) highlighted the participation of SGO2 in DNA replication. Immunoinfiltration analysis indicated a connection between SGO2 and several immune cell types, with single-cell analysis verifying SGO2 expression across diverse cell populations. Conclusion: SGO2 may serve as a valuable prognostic biomarker and a potential therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.